Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
May 13 2024 - 6:00AM
Business Wire
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical
company, is pleased to announce the appointment of Greg DiPasquale
as Senior Vice President, Head of Commercial, effective
immediately. DiPasquale will oversee sales, marketing, and sales
operations for Harrow’s rapidly growing portfolio of branded
ophthalmic products. This new role reflects Harrow’s commitment to
enhancing its leadership structure to support the Company’s
continued growth. John Saharek, Harrow’s Chief Commercial Officer
and Chief Executive Officer of ImprimisRx, will continue to oversee
Harrow’s commercial business, focusing on the day-to-day management
of Harrow’s market‑leading compounded division.
DiPasquale joins Harrow from Regeneron Pharmaceuticals, Inc.,
where he served as National Business Director and was responsible
for key account management and national sales of the anti-VEGF
products EYLEA® and EYLEA® HD for its two highest volume
indications. Under his leadership, sales of products under Greg’s
portfolio grew from $4.5 billion to over $6 billion during a
four-year period. Prior to this role, DiPasquale was Vice President
and Head of Sales for the newly formed Retina Division of Novartis
Ophthalmology, where he oversaw the development of the division’s
sales infrastructure, spearheaded the launch of BEOVU®, and
expanded the entire retina and ophthalmology product pipeline,
generating over $1 billion in revenues in 2020. DiPasquale’s
extensive experience also includes executive leadership positions
at Bausch + Lomb as Vice President of Sales for the U.S. Vision
Care business, at Zeiss Vision Care as Senior Vice President, with
responsibility for profit and loss for its eyecare professional
practice and the management of multiple lab operations and sales
personnel throughout the U.S., and at Essilor USA. DiPasquale holds
a Bachelor’s in Business Administration (BBA) from Ohio University
and an Executive MBA from Kent State University. DiPasquale will be
based in Harrow’s Nashville, Tennessee, corporate headquarters.
Commenting on DiPasquale’s addition to the Harrow team, Mark L.
Baum, Chairman and Chief Executive Officer of Harrow, said, “Over
the last 16 years of Greg’s remarkable career, he has delivered
outstanding economic and commercial results, playing a pivotal role
in commercializing several highly successful ophthalmic
pharmaceutical products. We are particularly excited about Greg’s
experience and proven success serving the buy-and-bill, retina, and
optometric markets given our recent launches of IHEEZO® and our
plans to re-launch TRIESENCE® – products with large retina market
opportunities – and our strong launch of VEVYE®, which has been so
positively embraced by the medical optometric market as well as by
ophthalmologists across the country. We are confident that Greg’s
strategic acumen and track record of expanding major ophthalmic
pharmaceutical franchises will prove invaluable to our success as
we continue to leverage our branded product portfolio and execute
our strategic plan to position Harrow as a leader in the North
American ophthalmic pharmaceutical market.”
DiPasquale added, “I am exceedingly enthusiastic about joining
Harrow, a dynamic, visionary, and service‑oriented company
committed to enhancing patient access to critical eyecare
medications. Leaders in eyecare have watched with admiration as
Harrow has evolved into a significant strategic player in the
ophthalmic pharmaceutical industry, starting from scratch with its
ImprimisRx franchise and subsequently acquiring 18 branded products
over the past two years. I look forward to utilizing the knowledge
and experience gained throughout my 30+ year career to advance
Harrow’s broad array of branded products, including, among others,
IHEEZO, VEVYE, and soon TRIESENCE, and to working with the talented
and dedicated Harrow team to take our company to the next
level.”
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical
company engaged in the discovery, development, and
commercialization of innovative ophthalmic pharmaceutical products
for the North American market. Harrow helps eyecare professionals
preserve the gift of sight by making its comprehensive portfolio of
prescription and non-prescription pharmaceutical products
accessible and affordable to millions of patients each year. For
more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include, among others, risks related to: liquidity or
results of operations; our ability to successfully implement our
business plan, develop and commercialize our products, product
candidates and proprietary formulations in a timely manner or at
all, identify and acquire additional products, manage our pharmacy
operations, service our debt, obtain financing necessary to operate
our business, recruit and retain qualified personnel, manage any
growth we may experience and successfully realize the benefits of
our previous acquisitions and any other acquisitions and
collaborative arrangements we may pursue; competition from
pharmaceutical companies, outsourcing facilities and pharmacies;
general economic and business conditions, including inflation and
supply chain challenges; regulatory and legal risks and
uncertainties related to our pharmacy operations and the pharmacy
and pharmaceutical business in general; physician interest in and
market acceptance of our current and any future formulations and
compounding pharmacies generally. These and additional risks and
uncertainties are more fully described in Harrow’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K and its Quarterly Reports on Form 10-Q. Such documents
may be read free of charge on the SEC's web site at sec.gov. Undue
reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward-looking
statements to reflect new information, events, or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513390675/en/
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Oct 2024 to Oct 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Oct 2023 to Oct 2024